Currently Dr Reddy’s, Cipla and Zydus derive significant portion of their earnings from generic Revlimid; Realisations on generic Revlimid can fall in second half of ...

Repurposed Drug use for cancer is exploding around the world. And today, New Year’s Day 2025, even Artificial Intelligence is ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Dr. Reddys Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

B&K Securities is bullish on CarTrade Tech Ltd., and holds that the company is a classic non-linear business with growth ...

Return expectations moderated for 2024 due to the statistical effect of a high base, but mid-high single-digit returns are ...

INR:4117. online indian horse race betting What is Sanofi’s new strategy after changing leadership, laying off employees, and adjusting pipelin ...

INR:3848. gym tshirt for men BeiGene's REVLIMID Approved for Third Indication for the Treatment of Relapsed/Refractory Indolent Lymphoma c-Met inhibitors enter ...

kerala jackpot result today guessing Singapore found two more confirmed cases of new coronary pneumonia, one male and one ...

INR:4251. nfl betting cards Celgene's Revlimid combination regimen for the treatment of follicular lymphoma is recommended by NICE! AstraZeneca's BTK inhibitor ...